Insulet Corporation (PODD)

NASDAQHealth CareMedical DevicesSnapshot 2026-07-08

$157.46-2.53%

Close 2026-07-08 · 1-day change

Reading PODD? This analysis is rebuilt every market day. Get it tracked free. No credit card.

Track PODD free→

The thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Compounder

The bull case

Insulet grows revenue about 23% a year. Profit margin is near 17%. The company buys back shares to help shareholders. New product updates improve its insulin delivery system.

The bear case

Product recalls and legal issues could hurt sales and reputation. Management changes add uncertainty. Guidance cuts show growth risks ahead.

What's priced in

The price is about 25% below our fair value near $215. Analysts expect 23% revenue growth. Our view aligns with this but sees risks from recent guidance cuts.

What has to stay true

No major product recalls or safety issuesBroken
RegulatoryprimaryNo voluntary medical device corrections or recalls · next 4 quarters (qualitative)
Breaks if: New major product recall or safety correction announced
Operating profit margin near 17.4% in 2025Intact
Marginprimary>=17.3% operating margin · FY25 (guidance)
Breaks if: Operating margin falls below 16% in FY25
Revenue grows about 23% in 2026Under Pressure
Revenue Growthprimary22% to 24% YoY growth · FY26 (qualitative)
Breaks if: YoY revenue growth falls below 22% in FY26
Are they delivering?On Track this quarter· 1 tracked commitment
- Increase revenue growth outlookGrowth
  Insulet aims to increase its revenue growth outlook, reflecting progress in its strategic initiatives.
  On Track
  Stated in 4 of last 4 quarters. Revenue grew from $569M in 2025-Q1 to $761.7M in 2026-Q1, indicating strong growth. The company is delivering on its revenue growth outlook, consistently raising guidance to reflect progress.
Repurchase at least 1.25 million sharesIntact
Capital Allocationsupporting>=1.25 million shares repurchased · next 4 quarters (qualitative)
Breaks if: Repurchases drop below 1 million shares in next year
Are they delivering?Mixed this quarter· 1 tracked commitment
- Share repurchase program expansionCapital allocation
  Insulet has expanded its share repurchase program to enhance shareholder value.
  Mixed
  Stated in 2 of last 2 quarters. The company repurchased 1.25 million shares of common stock, reflecting its commitment to the expanded repurchase program. This aligns with the priority to enhance shareholder value through capital allocation.

Standing thesis, reviewed periodically — not a price target or advice.

Read the full Outlook — the long-form 1–3 year hold read

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.